秋田大学大学院医学系研究科 医学専攻
腫瘍制御医学系 臨床腫瘍学講座 Department of Clinical Oncology, Akita University Graduate School of Medicine 秋田大学医学部附属病院 化学療法部/
秋田大学医学部附属病院 腫瘍内科 Department of Clinical Oncology / Division of Cancer Chemotherapy, Akita University Hospital

トップページ＞講座概要＞がん薬物療法の更なる進歩を期して＞文献

がん薬物療法の更なる進歩を期して

文献

  1. 厚生統計協会 (2008). 国民衛生の動向. 厚生の指標; 55（増刊）
  2. 佐藤春彦、神部真理子、渡辺紀予子、他 (1991) 臨床癌化学療法部門入院患者の化学療法概要（1978-1990年）. 抗酸菌病研究所雑誌　第43巻. 139-149.
  3. Shibata H, Toyama K, Shioya H, et al. (1997) Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. Science, 278, 120-123.
  4. Shibata H, Takano H, Ito M, et al. (2007) Alpha-catenin is essential in intestinal adenoma formation. Proc Natl Acad Sci U S A., 104, 18199-18204.
  5. Psaty BM, Potter JD. (2006) Risks and benefits of celecoxib to prevent recurrent adenomas. N Engl J Med., 355, 950-952.
  6. Gilman A (1963) The initial clinical trial of nitrogen mustard. Am. J. Surg., 105, 574-578.
  7. Li MC, Hertz R, Bergenstal DM. (1958) Therapy of choriocarcinoma and related trophoblastic tumors with folic acid and purine antagonists. N. Engl. J. Med., 259, 66-74.
  8. Kopetz S, Chang GJ, Overman MJ, et al. (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol., 27, 3677-3683.
  9. Kantarjian H, Sawyers C, Hochhaus A, et al., (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med., 346, 645-652.
  10. Druker BJ, Sawyers CL, Kantarjian H, et al., (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med., 344, 1038-1042.
  11. de Gramont A, Bosset JF, Milan C, et al. (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. ,15, 808-815.
  12. Kohne CH, Wils J, Lorenz M, et al. (2003) Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol., 21, 3721-3728.
  13. Tournigand C, Andre T, Achille E, et al. (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol., 22, 229-237.
  14. de Gramont A, Figer A, Seymour M, et al. (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol., 18, 2938-2947.
  15. Cheeseman SL, Joel SP, Chester JD, et al. (2002) A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer., 87, 393-399.
  16. Fuchs CS, Marshall J, Barrueco J. (2008) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol., 26, 689-690.
  17. Saltz LB, Clarke S, Diaz-Rubio E, et al. (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin Oncol., 26, 2013-2019.
  18. Van Cutsem E, Kohne CH, Hitre E, et al. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med., 360, 1408-1417.
  19. Bokemeyer C, Bondarenko I, Makhson A, et al. (2007) Cetuximab plus 5FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. J Clin Oncol. 25: 4035. ASCO Annual Meeting Proceedings, Part I.
  20. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med., 359, 1757-1765.
  21. Amado RG, Wolf M, Peeters M, et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol., 26, 1626-1634.
  22. Van Cutsem E, Rivera F, Berry S, et al (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 20, 1842-1847.
  23. Van Cutsem E. (2006) Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist. 11, 1010-1017.
  24. Cassidy J, Tabernero J, Twelves C, et al. (2004) XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 22, 2084-2091.
  25. Sakar B, Gumus M, Basaran M, et al. (2007) XELOX followed by XELIRI or the reverse sequence in advanced colorectal cancer. Oncology. 73, 298-304.
  26. Yamada Y, Tahara M, Miya T, et al. (2008) Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer. Br J Cancer. 98, 1034-1038.
  27. Yoshioka T, Kato S, Gamoh M, et al. (2009) Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer. Br J Cancer. 101, 1972-1977.
  28. Bode AM, Dong Z. (2009) Cancer prevention research - then and now.Nat Rev Cancer. 9, 508-516.
  29. Ohori H, Yamakoshi H, Tomizawa M, et al. (2006) Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer. Mol Cancer Ther., 5, 2563-2571.
  30. Shibata H, Yamakoshi H, Sato A, et al. (2009) Newly synthesized curcumin analog has improved potential to prevent colorectal carcinogenesis in vivo. Cancer Sci., 100, 956-960.

←前のページへ　↑ページ上部へ

図表について

  • 図-1.東北大学化学療法科と仙台厚生病院消化器科（1978-1990）における進行がん患者統計
  • 図-2. がん生物学の進歩とがんという病態の理解
  • 図-3. ノックアウトマウスを用いた発がん研究
  • 図-4. コンディショナルノックアウトマウスを用いた大腸発がん研究
  • 図-5. コンディショナルノックアウトを用いた各種臓器における発がん研究
  • 図-6. 大腸発がんのmodifier遺伝子の探索
  • 図-7. 大腸発がんのmodifier遺伝子の同定=α-Catenin
  • 図-8. マウスモデルからの教訓～“分子レベルでの発がんの制御”
  • 図-9. 大腸がん化学療法の進歩
  • 図-10. 分子標的化合物ー“クルクミン”
  • 図-11. クルクミンアナログの抗腫瘍活性
  • 表　近年の化学療法による治療効果

←前のページへ　↑ページ上部へ

▲ページ上部へ